Prophylactic bilateral salpingectomy: why is it worthwhile?

1Didkowska J, Wojciechowska U. Nowotwory złośliwe w Polsce w 2013 roku. Krajowy Rejestr Nowotworów. Warszawa 2015.Didkowska J Wojciechowska U Nowotwory złośliwe w Polsce w 2013roku. Krajowy Rejestr Nowotworów Warszawa 2015Search in Google Scholar

2Markowska A. Epidemiologia i etiopatogeneza raka jajnika W: Markowska J, Mądry R (Red.) Zarys Ginekologii Onkologicznej. Tom II. Termedia, Poznań, 2015.Markowska A Epidemiologia i etiopatogeneza raka jajnika W: Markowska J, Mądry R (Red.) Zarys Ginekologii Onkologicznej. Tom II Termedia, Poznań 2015Search in Google Scholar

3Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E on behalf of the ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 2016;27:103-110.Paluch-Shimon S Cardoso F Sessa C Balmana J Cardoso MJ Gilbert F Senkus E on behalf of the ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening Ann Oncol 201627103 11010.1093/annonc/mdw327Search in Google Scholar

4American College of Obstetricians and Gynecologists. Committee Opinion No. 620. Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015;125:279-281.American College of Obstetricians and Gynecologists Committee Opinion No 620. Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015125279 28110.1097/01.AOG.0000459871.88564.09Search in Google Scholar

5WHO Classification of Ovarian Neoplasms. PathologyOutlines. com: http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html Dostęp: 01.10.2018.WHO Classification of Ovarian Neoplasms. PathologyOutlines. com http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html Dostęp: 01.10.2018Search in Google Scholar

6Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-1197.Dubeau L The cell of origin of ovarian epithelial tumours Lancet Oncol 200891191 119710.1016/S1470-2045(08)70308-5Search in Google Scholar

7Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10:296-306.Tone AA Salvador S Finlayson SJ Tinker AV Kwon JS Lee CH Cohen T Ehlen T Lee M Carey MS et al The role of the fallopian tube in ovarian cancer Clin Adv Hematol Oncol 201210296 306Search in Google Scholar

8Kurman R, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol 2010;33:433-443.Kurman R Shih I-M The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory Am J Surg Pathol 201033433 44310.1097/PAS.0b013e3181cf3d79284179120154587Search in Google Scholar

9Nik NN, Vang R, Shih I-M, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol Mech Dis 2014;9:2745.Nik NN Vang R Shih I-M Kurman RJ Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma Annu Rev Pathol Mech Dis 20149274510.1146/annurev-pathol-020712-16394923937438Search in Google Scholar

10Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for casual relationship. Am J Surg Pathol 2007;31:161-169.Kindelberger DW Lee Y Miron A Hirsch MS Feltmate C Medeiros F Callahan MJ Garner EO Gordon RW Birch C et al Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for casual relationship Am J Surg Pathol 200731161 16910.1097/01.pas.0000213335.40358.4717255760Search in Google Scholar

11Singh R, Cho KR. Serous tubal intraepithelial carcinoma or not? Metastases to fallopian tube mucosa can masquerade as in situ lesions. Arch Pathol Lab Med 2017;141:1313-1315.Singh R Cho KR Serous tubal intraepithelial carcinoma or not? Metastases to fallopian tube mucosa can masquerade as in situ lesions Arch Pathol Lab Med 20171411313 131510.5858/arpa.2017-0231-RA28968160Search in Google Scholar

12Trabert B, Coburn SB, Mariani A, Yang HP, Rosenberg PS, Gierach GL, Wentzensen N, Cronin KA, Sherman ME. Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries. J Natl Cancer Inst 2018;110:750-757.Trabert B Coburn SB Mariani A Yang HP Rosenberg PS Gierach GL Wentzensen N Cronin KA Sherman ME Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries J Natl Cancer Inst 2018110750 75710.1093/jnci/djx263603712429281053Search in Google Scholar

13Venturella R, Lico D, Borelli M, Imbrogno MG, Cevenini G, Zupi E, Zullo F, Morelli M. 3 to 5 years later: Long-term effects of prophylactic bilateral salpingectomy on ovarian function. J Minim Invasive Gynecol 2017;24:145-150.Venturella R Lico D Borelli M Imbrogno MG Cevenini G Zupi E Zullo F Morelli M 3 to 5 years later: Long-term effects of prophylactic bilateral salpingectomy on ovarian function J Minim Invasive Gynecol 201724145 15010.1016/j.jmig.2016.08.83327621194Search in Google Scholar

14McAlpine JN, Hanley GE, Woo MMM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM for the Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210:471. e1-471.e11.McAlpine JN Hanley GE Woo MMM Tone AA Rozenberg N Swenerton KD Gilks CB Finlayson SJ Huntsman DG Miller DM for the Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention Am J Obstet Gynecol 2014210471 e1-471.e1110.1016/j.ajog.2014.01.00324412119Search in Google Scholar

15Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, D’Alessandro P, Zullo F. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere. Gynecol Oncol 2013;129:448-451.Morelli M Venturella R Mocciaro R Di Cello A Rania E Lico D D’Alessandro P Zullo F. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere Gynecol Oncol 2013129448 45110.1016/j.ygyno.2013.03.02323558052Search in Google Scholar

16Kwon JS. Ovarian cancer risk reduction through opportunistic salpingectomy. J Gynecol Oncol 2015;26:83-86.Kwon JS Ovarian cancer risk reduction through opportunistic salpingectomy J Gynecol Oncol 20152683 8610.3802/jgo.2015.26.2.83439723625872888Search in Google Scholar

17Finlayson S for the BC’s Ovarian Cancer Research Team. Advocating Fallopian Tube removal at the time of hysterectomy to prevent ovarian cancer. http://www.ovcare.ca/prevention/for_health_professionals Dostęp: 01.10.2018.Finlayson S for the BC’s Ovarian Cancer Research Team. Advocating Fallopian Tube removal at the time of hysterectomy to prevent ovarian cancer http://www.ovcare.ca/prevention/for_health_professionals Dostęp: 01.10.2018Search in Google Scholar

18Lin YJ, Ou YC, Huang FJ, Lin PY, Kung FT, Lan KC. Ovarian response to gonadotropins in patients with tubal factor infertility: salpingectomy versus nonsalpingectomy. J Minim Invasive Gynecol 2013;20:637-641.Lin YJ Ou YC Huang FJ Lin PY Kung FT Lan KC Ovarian response to gonadotropins in patients with tubal factor infertility: salpingectomy versus nonsalpingectomy J Minim Invasive Gynecol 201320637 64110.1016/j.jmig.2013.04.00523706676Search in Google Scholar

19Skorupska KA, Miotła P. Are there any differences in quality of life and sexual functions after various types of hysterectomy – does prophylactic salpingectomy matter? Ginekol Pol 2016;87:26-31.Skorupska KA Miotła P Are there any differences in quality of life and sexual functions after various types of hysterectomy – does prophylactic salpingectomy matter? Ginekol Pol 20168726 3110.17772/gp/6055427306465Search in Google Scholar

20Dilley SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, Straughn Jr JM, Caughey AB, Rodriguez MI. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol 2017;146:373-379.Dilley SE Havrilesky LJ Bakkum-Gamez J Cohn DE Straughn Jr JM Caughey AB Rodriguez MI. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention Gynecol Oncol 2017146373 37910.1016/j.ygyno.2017.05.03428577884Search in Google Scholar

21Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD et al. for the Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185-192.Finch A Beiner M Lubinski J Lynch HT Moller P Rosen B Murphy J Ghadirian P Friedman E Foulkes WD et al for the Hereditary Ovarian Cancer Clinical Study Group Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006 296185 19210.1001/jama.296.2.18516835424Search in Google Scholar

22Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.Domchek SM Friebel TM Singer CF Evans DG Lynch HT Isaacs C Garber JE Neuhausen SL Matloff E Eeles R et al Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 2010304967 97510.1001/jama.2010.1237294852920810374Search in Google Scholar

23Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J for the Kommission Ovar of the Gynecologic Oncology Study Group (AGO). Should fallopian tubes be removed during hysterectomy procedures? – A statement by AGO Ovar / Sollen die Tuben im Rahmen der Hysterektomie entfernt werden? – Ein Statement der AGO Ovar. Geburtshilfe Frauenheilkd 2015;75:339-341.Pölcher M Hauptmann S Fotopoulou C Schmalfeldt B Meinhold-Heerlein I Mustea A Runnebaum I Sehouli J for the Kommission Ovar of the Gynecologic Oncology Study Group (AGO). Should fallopian tubes be removed during hysterectomy procedures? – A statement by AGO Ovar / Sollen die Tuben im Rahmen der Hysterektomie entfernt werden? – Ein Statement der AGO Ovar Geburtshilfe Frauenheilkd 201575339 34110.1055/s-0035-1545958443775226028692Search in Google Scholar

24Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011;70:261-265.Finch A Narod SA Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review Maturitas 201170261 26510.1016/j.maturitas.2011.08.00121893388Search in Google Scholar

25Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011;121:163-168.Finch A Metcalfe KA Chiang JK Elit L McLaughlin J Springate C Demsky R Murphy J Rosen B Narod SA The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation Gynecol Oncol 2011121163 16810.1016/j.ygyno.2010.12.32621216453Search in Google Scholar

26National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.Dostęp 26.10.2018.National Comprehensive Cancer Network https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.Dostęp 26.10.2018Search in Google Scholar

27National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Dostęp: 26.10.2018.National Comprehensive Cancer Network https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Dostęp: 26.10.2018Search in Google Scholar

28Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience 2018;12:803.Dawson A Fernandez ML Anglesio M Yong PJ Carey MS Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development Ecancermedicalscience 20181280310.3332/ecancer.2018.803581391929456620Search in Google Scholar